Spyre Therapeutics, Inc. (SYRE)
NASDAQ
Closed
Oct 8, 2026
Day's Range
77.0552 wk Range
16.04Overview - SYRE - Spyre Therapeutics, Inc.
Key Statistics
Valuation
Enterprise Value
7.21B
P/E (Trailing)
‪1.68‬
P/E (Forward)
‪-26.47‬
PEG Ratio
‪-0.05‬
Price / Book
‪8.59‬
EV / EBITDA
‪-31.44‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-19.81%‬
Return on Equity
‪-22.98%‬
Ownership
Shares Outstanding
88.06M
Float
82.14M
Short % of Shares Outstanding
‪14.71%‬
Held by Insiders
‪1.67%‬
Held by Institutions
‪111.46%‬
Price stats
Beta
‪3.00‬
50-Day Avg
‪95.98‬
200-Day Avg
‪67.63‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
17 analysts
Average price target
‪$ 124.71‬Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - SYRE - Spyre Therapeutics, Inc.
Peers - SYRE - Spyre Therapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- SYRENASDAQSpyre Therapeutics, Inc.8.05BMarket Cap+82.02%52-week change1.68P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQArgenx SE57.50BMarket Cap+14.28%52-week change34.96P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.40BMarket Cap-105.72%52-week change38.35P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.34BMarket Cap-8.52%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.99BMarket Cap+7.48%52-week change17.72P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.14BMarket Cap+18.80%52-week change-17.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - SYRE - Spyre Therapeutics, Inc.
About
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing long-acting antibodies and antibody combinations for inflammatory bowel disease and other immune-mediated disorders. Spyre Therapeutics concentrates on advancing therapies designed to improve disease control, extend treatment…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
